(19)
(11) EP 4 296 373 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.03.2025 Bulletin 2025/13

(45) Mention of the grant of the patent:
19.02.2025 Bulletin 2025/08

(21) Application number: 23189043.5

(22) Date of filing: 04.10.2019
(51) International Patent Classification (IPC): 
C12Q 1/6806(2018.01)
 C12Q 1/6865(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6806; C12Q 2600/166; C12Q 1/6876; C12Q 2525/131; C12Q 2525/143; C12Q 2535/122; C12Q 2545/101; C12Q 1/6865
 
C-Sets:
  1. C12Q 1/6806, C12Q 2525/131, C12Q 2525/143, C12Q 2525/204, C12Q 2535/122, C12Q 2545/101, C12Q 2545/113;
  2. C12Q 1/6865, C12Q 2525/131, C12Q 2525/143, C12Q 2535/122, C12Q 2545/101;

(54)

NORMALIZATION CONTROLS FOR MANAGING LOW SAMPLE INPUTS IN NEXT GENERATION SEQUENCING

NORMALISIERUNGSSTEUERUNG ZUR VERWALTUNG GERINGER PROBENEINGABEN IN DER NEXT-GENERATION-SEQUENZIERUNG

COMMANDES DE NORMALISATION POUR GÉRER DE FAIBLES ENTRÉES D'ÉCHANTILLON DANS LE SÉQUENÇAGE DE NOUVELLE GÉNÉRATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 04.10.2018 US 201862741466 P
11.04.2019 US 201962832560 P

(43) Date of publication of application:
27.12.2023 Bulletin 2023/52

(62) Application number of the earlier application in accordance with Art. 76 EPC:
19794317.8 / 3861135

(73) Proprietor: Arc Bio, LLC
Scotts Valley, CA 95066 (US)

(72) Inventors:
  • HARNESS, Eric
    CA 94086 Sunnyvale (US)
  • NAGESH, Vaishnavi
    MA 02141, Cambridge (US)
  • BENTLEY, Lloyd Gordon
    MA 02141 Cambridge (US)
  • CARPENTER, Meredith L.
    CA 94401 San Mateo (US)

(74) Representative: Boult Wade Tennant LLP 
Salisbury Square House 8 Salisbury Square
London EC4Y 8AP
London EC4Y 8AP (GB)


(56) References cited: : 
   
  • LESHKOWITZ DENA ET AL: "Using Synthetic Mouse Spike-In Transcripts to Evaluate RNA-Seq Analysis Tools", PLOS ONE, vol. 11, no. 4, 21 April 2016 (2016-04-21), pages e0153782, XP093100733, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839710/pdf/pone.0153782.pdf> DOI: 10.1371/journal.pone.0153782
  • SIMON A HARDWICK ET AL: "Spliced synthetic genes as internal controls in RNA sequencing experiments", NATURE METHODS, vol. 13, no. 9, 1 September 2016 (2016-09-01), New York, pages 792 - 798, XP055535717, ISSN: 1548-7091, DOI: 10.1038/nmeth.3958
  • MAURO D. LOCATI ET AL: "Improving small RNA-seq by using a synthetic spike-in set for size-range quality control together with a set for data normalization", NUCLEIC ACIDS RESEARCH ADVANCE ACCESS, vol. 43, no. 14, 18 August 2015 (2015-08-18), GB, pages e89 - e89, XP055386708, ISSN: 0305-1048, DOI: 10.1093/nar/gkv303
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).